MedPath

Bintrafusp alfa

Generic Name
Bintrafusp alfa
Drug Type
Biotech
CAS Number
1918149-01-5
Unique Ingredient Identifier
NW9K8C1JN3

Overview

Bintrafusp alfa is under investigation in clinical trial NCT03833661 (M7824 Monotherapy in Locally Advanced or Metastatic Second Line (2L) Biliary Tract Cancer (Cholangiocarcinoma and Gallbladder Cancer)).

Background

Bintrafusp alfa is under investigation in clinical trial NCT03833661 (M7824 Monotherapy in Locally Advanced or Metastatic Second Line (2L) Biliary Tract Cancer (Cholangiocarcinoma and Gallbladder Cancer)).

Indication

No indication information available.

Associated Conditions

No associated conditions information available.

Clinical Trials

Title
Posted
Study ID
Phase
Status
Sponsor
2022/07/06
Phase 2
Withdrawn
2021/09/30
Phase 3
Completed
2021/08/13
Phase 2
Recruiting
Fundación GECP
2021/07/21
Phase 2
Terminated
2021/05/07
Phase 2
Not yet recruiting
2021/05/05
Phase 2
Recruiting
2021/03/09
Phase 1
Completed
2021/02/16
Phase 1
Withdrawn
2021/01/27
Phase 2
Terminated
2021/01/14
Phase 1
Active, not recruiting

FDA Drug Approvals

Approved Product
Manufacturer
NDC Code
Route
Strength
Effective Date
No FDA approvals found for this drug.

EMA Drug Approvals

Approved Product
Authorization Holder
Status
Issued Date
No EMA approvals found for this drug.

HSA Drug Approvals

Approved Product
Manufacturer
Approval Number
Dosage Form
Strength
Approval Date
No HSA approvals found for this drug.

NMPA Drug Approvals

Approved Product
Company
Approval Number
Drug Type
Dosage Form
Approval Date
No NMPA approvals found for this drug.

PPB Drug Approvals

Approved Product
Registration No.
Company
Licence No.
Strength
Registration Date
No PPB approvals found for this drug.

TGA Drug Approvals

Approved Product
ARTG ID
Sponsor
Registration Type
Status
Registration Date
No TGA approvals found for this drug.
© Copyright 2025. All Rights Reserved by MedPath